FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2284998315> ?p ?o ?g. }

• W2284998315 endingPage "A134" @default.
• W2284998315 startingPage "A133" @default.
• W2284998315 abstract "Clinical trials comparing rivaroxaban or dabigatran to warfarin show similar results for major and non-major clinically relevant bleeding. Post-marketing data regarding bleeding rates for these new oral anticoagulants (NOACs) is lacking. Our goal was to evaluate bleeding related outcomes with NOACs using a disproportionality analysis of spontaneous adverse event reports. We evaluated the FAERS database from 10/2011 – 12/2012 to compare frequency of events in reports of rivaroxaban, dabigatran, and warfarin related to fatal and non-fatal bleeding. Reports were included if the anticoagulant was the primary suspected agent for the event. Reporting odds ratio (ROR) and proportional reporting ratio (PRR) were calculated to estimate risk for each anticoagulant. Of 22,244 eligible adverse drug reports for the anticoagulants, 7661 (34%) bleeding reports were submitted, with 1868 (24%) deaths, 5028 (66%) hospitalizations and 1040 (14%) life-threatening events. Dabigatran was the most commonly reported anticoagulant exposure among bleeding cases (n=5203, 68%). Of the bleeding cases associated with dabigatran, death was reported in 29%, hospitalization in 67%, and life-threatening events in 15% of cases. The odds of exposure for fatal bleeding was significantly higher with dabigatran (ROR 2.28, 95% confidence interval [CI] 2.02-2.56) and significantly lower with rivaroxaban (ROR 0.75, CI = 0.69-0.8) and warfarin (ROR 0.53, CI = 0.44-0.63). PRR indicated significantly increased risk of non-fatal bleeding with dabigatran (PRR = 2.12, CI = 1.99-2.24) and warfarin (PRR = 1.27, CI = 1.17-1.38) with a significant decrease associated with rivaroxaban (PRR 0.8, CI = 0.75-0.86). Among the NOACs, patients having fatal and non-fatal bleeding were found to have higher odds of dabigatran exposure and significantly lower odds of rivaroxaban exposure. Though FAERS is subject to significant bias, the results suggest dabigatran-related bleeding is higher in clinical practice and rivaroxaban may be a safer alternative." @default.
• W2284998315 created "2016-06-24" @default.
• W2284998315 creator A5012828180 @default.
• W2284998315 creator A5024834543 @default.
• W2284998315 creator A5025259407 @default.
• W2284998315 date "2015-05-01" @default.
• W2284998315 modified "2023-09-26" @default.
• W2284998315 title "Evaluation Of Bleeding Outcomes Linked To New Oral Anticoagulants: Review Of The Fda Adverse Event Reporting System (Faers)" @default.
• W2284998315 doi "https://doi.org/10.1016/j.jval.2015.03.778" @default.
• W2284998315 hasPublicationYear "2015" @default.
• W2284998315 type Work @default.
• W2284998315 sameAs 2284998315 @default.
• W2284998315 citedByCount "0" @default.
• W2284998315 crossrefType "journal-article" @default.
• W2284998315 hasAuthorship W2284998315A5012828180 @default.
• W2284998315 hasAuthorship W2284998315A5024834543 @default.
• W2284998315 hasAuthorship W2284998315A5025259407 @default.
• W2284998315 hasBestOaLocation W22849983151 @default.
• W2284998315 hasConcept C126322002 @default.
• W2284998315 hasConcept C156957248 @default.
• W2284998315 hasConcept C197934379 @default.
• W2284998315 hasConcept C2776301958 @default.
• W2284998315 hasConcept C2777105317 @default.
• W2284998315 hasConcept C2778205648 @default.
• W2284998315 hasConcept C2778661090 @default.
• W2284998315 hasConcept C2778810321 @default.
• W2284998315 hasConcept C2779161974 @default.
• W2284998315 hasConcept C44249647 @default.
• W2284998315 hasConcept C71924100 @default.
• W2284998315 hasConceptScore W2284998315C126322002 @default.
• W2284998315 hasConceptScore W2284998315C156957248 @default.
• W2284998315 hasConceptScore W2284998315C197934379 @default.
• W2284998315 hasConceptScore W2284998315C2776301958 @default.
• W2284998315 hasConceptScore W2284998315C2777105317 @default.
• W2284998315 hasConceptScore W2284998315C2778205648 @default.
• W2284998315 hasConceptScore W2284998315C2778661090 @default.
• W2284998315 hasConceptScore W2284998315C2778810321 @default.
• W2284998315 hasConceptScore W2284998315C2779161974 @default.
• W2284998315 hasConceptScore W2284998315C44249647 @default.
• W2284998315 hasConceptScore W2284998315C71924100 @default.
• W2284998315 hasIssue "3" @default.
• W2284998315 hasLocation W22849983151 @default.
• W2284998315 hasOpenAccess W2284998315 @default.
• W2284998315 hasPrimaryLocation W22849983151 @default.
• W2284998315 hasRelatedWork W2582505536 @default.
• W2284998315 hasRelatedWork W2606162097 @default.
• W2284998315 hasRelatedWork W2741829680 @default.
• W2284998315 hasRelatedWork W2750718596 @default.
• W2284998315 hasRelatedWork W2799781758 @default.
• W2284998315 hasRelatedWork W2800282599 @default.
• W2284998315 hasRelatedWork W2888737521 @default.
• W2284998315 hasRelatedWork W2908436399 @default.
• W2284998315 hasRelatedWork W2917668813 @default.
• W2284998315 hasRelatedWork W3202697683 @default.
• W2284998315 hasVolume "18" @default.
• W2284998315 isParatext "false" @default.
• W2284998315 isRetracted "false" @default.
• W2284998315 magId "2284998315" @default.
• W2284998315 workType "article" @default.